Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

This publication has 39 references indexed in Scilit:

• Effect of Ramipril on the Incidence of Diabetes
  New England Journal of Medicine, 2006
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  Published by Elsevier ,2005
• Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  JAMA, 2002
• The Effects of Valsartan on Insulin Sensitivity in Patients with Primary Hypertension
  Journal of International Medical Research, 2002
• A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
  New England Journal of Medicine, 2001
• Global and societal implications of the diabetes epidemic
  Nature, 2001
• The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
  Journal of Clinical Investigation, 1999
• The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.
  Diabetes Care, 1999
• Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril
  Journal Of Hypertension, 1996
• Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland
  Diabetes Care, 1979